Clinical Evaluation of Novel Biomarkers for Diagnosis, Therapy- Monitoring and Prognosis of Outcome in Patients With Septicemia
The two most common causative pathogens of septicemia (Escherichia coli and Staphylococcus
aureus) as well as cases of fungemia (Candida spp., Aspergillus spp., and others) will be
included in the first study group. At our hospital the estimated yearly cases of
bacteremia/fungemia (230 for Escherichia coli, 150 for Staphylococcus aureus, and 50 for
fungi) will be included in the first study group. Furthermore, the two biomarkers will be
determined in 70 cases of septicemia with other bacterial pathogens and sepsis due to viral
pathogens or viremia for evaluation of further clinical impact of these two biomarkers.
Observational
Observational Model: Cohort, Time Perspective: Prospective
prognostic value of biomarkers in bacteremia
2 years
No
Martin Hoenigl, MD
Principal Investigator
Medical University of Graz
Austria: Ethikkommission
21-469
NCT01359891
November 2010
June 2014
Name | Location |
---|